Bristol-Myers' Opdivo fails to meet lung cancer study goal

Bristol-Myers Squibb Co said on Friday its blockbuster cancer drug Opdivo failed to meet the main goal in patients with a type of lung cancer, that had relapsed after chemotherapy.